We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Surgery Reduces Cancer Risk in Lynch Syndrome

By HospiMedica staff writers
Posted on 09 Feb 2006
Preventive surgery to remove the uterus and ovaries appears to greatly reduce the risk of developing endometrial or ovarian cancer among women with Lynch syndrome, a new study has reported. More...


Because women with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC) mutations, are at increased risk of developing endometrial and ovarian cancers, the researchers examined the extent to which cancer risk can be decreased by prophylactic surgery. Specifically, female mutation carriers may benefit from the surgical removal of their uterus (hysterectomy) and/or fallopian tubes and ovaries (salpingo-oophorectomy) before endometrial or ovarian cancer are diagnosed.

The researchers assessed cancer risk in 315 women who had undergone both hysterectomy and bilateral salpingo-oophorectomy (BSO), hysterectomy alone, or had not had prophylactic surgery at all. The results showed that endometrial cancer developed in 33% of women without prophylactic hysterectomy and none of the women with prophylactic hysterectomy. Ovarian cancer developed in 5.5% of the women without prophylactic BSO and none of the women with prophylactic BSO. The results were published in the January 19, 2006, edition of the New England Journal of Medicine.

Given the median ages at which endometrial and ovarian cancers developed in the women without prophylactic surgery (46 years for endometrial cancer and 42 years for ovarian cancer), the researchers noted that it may be appropriate to consider prophylactic surgery after the age of 35, or once childbearing has been completed.

"Women with the Lynch syndrome have a 40-60% lifetime risk of endometrial cancer and a 10-12% lifetime risk of ovarian cancer,” wrote Kathleen M. Schmeler, M.D., from the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA), and colleagues. "These findings suggest that prophylactic hysterectomy with BSO is an effective strategy for preventing endometrial and ovarian cancer in women with the Lynch syndrome.”

Lynch syndrome results from inherited mutations in genes involved in DNA mismatch repair. These mutations greatly increase the risk of developing colorectal cancer and also increase the risk of several other cancers. Overall, roughly 3-5% of all colorectal cancers are thought to result from HNPCC mutations.






Related Links:
University of Texas M.D. Anderson Cancer Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.